The subcutaneous implantable cardioverter-defibrillator: should patients want one?
Where this comes from
- Record sourced from PubMed, PMID 23122791.
- Also identified by DOI 10.1016/j.jacc.2012.07.069.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The subcutaneous implantable cardioverter-defibrillator is a novel device that does not require insertion of a transvenous lead; rather, it delivers 80-J transthoracic shocks via a subcutaneous pulse generator implanted in the left lateral chest and a subcutaneous left parasternal lead-electrode. It recently received approval by U.S. Food and Drug Administration panel on the basis of a 180-day study in 330 patients. However, it has not been shown to be non inferior to current implantable cardioverter-defibrillators, and it does not provide either anti-tachycardia or bradycardia pacing. Thus, is this technology ready for widespread application? Specifically, should a patient want one?
Medical subject headings
- Defibrillators, Implantable
- Subcutaneous Tissue